Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046059 · ClinicalTrials.gov registry record
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 3,481
- Enrollment target
NCT00046059: Completed study, sponsored by National Human Genome Research Institute (NHGRI).
NCT00046059 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 3,481 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046059 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 3,481 participants
- Enrollment target
Study Summary
Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder in childhood, affecting 3-5% of children between the ages of 7 and 17. Family studies suggest that there is a genetic component to ADHD. Scientists believe that it is a complex disorder in which two or more genes may be involved. Potentially eligible families will be asked to give written consent to participate and will be asked to complete questionnaires for each member in the family. In addition, an interview will be administered to the parent of minors enrolled in the study to determine their eligibility for being in the study. This screening tool is computerized and will take approximately 45 minutes to administer per child. Once screenings are completed, a blood collection kit will be sent to the family to take to their local medical care provider, have blood samples drawn and sent to NIH. There is no cost to the family to participate. We would like to enroll entire families, with both parents and all children.
Primary Outcome
The main objective of the study is to conduct genetic and behavioral studies that will closely characterize the genetic influences in diagnosis, prognosis, severity, and pharmacological response in ADHD patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,481 participants |
| Start Date | 2000-02-08 |
| Est. Completion | 2020-01-24 |
What the finished NCT00046059 record still lists
NCT00046059 is an observational study that tracks outcomes without assigning an intervention. Its 3,481 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00046059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00046059 about?
NCT00046059 is a clinical study titled "Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)". Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder in childhood, affecting 3-5% of children between the ages of 7 and 17. Family studies suggest that there is a genetic component to ADHD. Scientists believe that it is a complex disorder in which two or more genes ...
What is the current status of trial NCT00046059?
This trial is currently completed. The enrollment target is 3,481 participants. The study started on 2000-02-08. Estimated completion is 2020-01-24.
Who is sponsoring clinical trial NCT00046059?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI